Vivos Inc Files Critical Patent For Hydrogel Electron Beam Sterilization
Rhea-AI Summary
Vivos Inc (OTCQB: RDGL) has filed a provisional patent (No. 63/873,014) for a new electron beam (E-Beam) sterilization process for their hydrogel technology. The process, validated under ISO 11137, achieves a sterility assurance level of 10-6 - the highest standard for critical medical devices.
The new sterilization method offers significant advantages over their current filtration process, including improved reliability, cost-effectiveness, and enhanced scalability. This advancement benefits both their Radiogel® (human) and IsoPet® (animal) therapy product lines, positioning the company for broader market penetration and increased revenue opportunities.
Positive
- Achievement of 10-6 sterility assurance level, the highest standard for critical medical devices
- New process is more cost-effective and improves production yield compared to current filtration method
- Enhanced scalability for commercial growth and worldwide distribution
- Patent filing provides intellectual property protection
- Process benefits both human (Radiogel®) and animal (IsoPet®) therapy divisions
Negative
- None.
News Market Reaction – RDGL
On the day this news was published, RDGL gained 0.47%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Kennewick, WA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Vivos Inc filed a provisional patent No.: 63/873,014 - STERILE THERMOGELS
Vivos Inc. is pleased to announce the successful validation of a new electron beam (E-Beam) sterilization process for our hydrogel, marking a culmination of nearly a year of testing and validation of a process that was only viable because of the unique characteristics of our hydrogel. The validation was carried out under ISO 11137 by an international medical device accredited organization. Vivos applies these same high standards to both human (Radiogel®) and animal (Isopet®) therapies.
The E-Beam sterilization process is reproduceable and more reliable than our current filtration process, achieving a sterility assurance level of 10-6, which is the most rigorous sterility level; meaning there is a one in a million chance of a viable microorganism surviving, and it is the standard for critical medical devices that enter the body or compromised tissues, ensuring patient safety by minimizing infection risk.
Beyond the clinical advantages, the process is more cost-effective, improves production yield, and meaningfully enhances scalability as we prepare for commercial growth. The ability to efficiently produce and distribute sterile hydrogel and PrecisionGel for therapeutic agent dispersal worldwide, supports Vivos’ strategic path toward broader market penetration.
Importantly, the process will also drive greater manufacturing efficiency for IsoPet®, our animal health therapy, enabling more consistent supply and cost-effective production to meet growing veterinary demand. This dual benefit—advancing both human and animal health divisions—positions Vivos for stronger revenue opportunities while reinforcing our competitive differentiator through intellectual property protection.
Michael K. Korenko, Sc.D.
President & CEO, Vivos Inc.
Email: MKorenko@RadioGel.com
Follow Vivos Inc. on X (Twitter): @VivosIncUSA
Learn more about RadioGel® and IsoPet® at www.VivosInc.com
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, identified by terms such as “will,” “expects,” “plans,” “anticipates,” and “intends.” These statements involve risks and uncertainties that may cause actual results to differ materially, including challenges in executing business strategies, economic conditions, competition, regulatory changes, delays in clinic certifications, and other factors beyond Vivos Inc.’s control. For a detailed discussion of these risks, refer to the company’s filings with the Securities and Exchange Commission.
FAQ
What is the significance of Vivos Inc's (RDGL) new E-Beam sterilization patent?
How does the new sterilization process benefit RDGL's business operations?
What sterility assurance level does Vivos's new E-Beam process achieve?
Which Vivos Inc products will benefit from the new E-Beam sterilization process?
What is the patent number for Vivos's new sterilization technology?
